The Company is a Korea-based company mainly engaged in the research and development of biopharmaceuticals. The Company researching and developing antibody therapeutics to provide patients with the antibodies needed to cure the disease. The Company's major products include tanibirumab used for cancer treatment, among others. The Company also carries out technology transfer about its pipelines with domestic and overseas pharmaceutical companies. The Company was established on September 03, 2008. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on November 21, 2018.
Headquarters
2F, Yeongu 2-Dong, 70, Yuseong-Daero 1689Beon-Gil, Yuseong-Gu
Daejeon; Daejeon;
Contact Details: Purchase the Pharm Abcine Inc. report to view the information.
Website: http://www.pharmabcine.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service